Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula

Experimental: ASC(Autologous Adipose-derived Stem Cells) and Fibringlue, Comparator: Fibringlue, Study type: Interventional, Study design: Randomized

Inclusion criteria

• Patient who has obtained the consent of their legal representative if they are over 18 years of age and under 20 years of age.
• Patient is diagnosed with Crohn's disease.
• Patient who has one or more Crohn's fistulas .
• In the case of women of childbearing potential, patient who is negative for beta-HCG pregnancy tests at the screening visit.
• Patient is able to give written informed consent prior to study start and willing to comply with the study requirements.

Exclusion criteria

• Patient who participated in other clinical trials within 30 days prior to the start of this clinical trial, or who has not passed a period equal to five times of the half-life of the drug dosed in other clinical trials.
• Patient with a medical history or family history of Variant Creutzfeld Jakob Disease or related to this disease.
• Patient who is sensitive to anesthetic drugs or bovine-derived materials.
• Patient with autoimmune disease except for Crohn's disease.
• Patient with infectious diseases such as HBV, HCV and HIV.
• Patient with signs of Septicemia.
• Patient with Active Tuberculosis.(Including patient with Anal Tuberculosis)
• Pregnant or breast-feeding.
• . Is unwilling to use an acceptable method of birth control during the whole study.
• Patient with Inflammatory Bowel disease except for Crohn's disease.
• Patient who is sensitive to Fibringlue.
• Patient with a clinically relevant history of alcohol or drugs abuse, habitual smoking.
• Patient whose adipose tissue obtained by liposuction is insufficient to manufacture the Investigational product at the intended dose.
• Patient who is not able to understand the objective of the study or to comply with the study requirements.
• Patient who is considered by the investigator to have a significant disease which might impact the study.
• Patient who is considered not suitable for the study by investigator.
• Patient who is Active Crohn's disease with CDAI 450 or higher.
• Patient with medical history of surgery for malignant cancer in the past 5 years.(Except for carcinoma in situ)
• Patient who exceeds 2 cm in the longest diameter of fistula.
• Patient who dosed anti-TNF formulations such as infliximab, adalimumab, certolizumab within 3 months prior to injection.